血管内卒中治疗中的血流动力学状态:血压与功能结局的相关性
该研究为单中心前瞻性研究的的事后分析,评估血管内治疗期间按方案管理血压的患者。纳入139例成功再通(脑梗死溶栓分级2b-3)患者,分析基线、再通前、再通后和术后四个阶段的血压与3个月改良Rankin量表评分0-2分的关系。结果显示,基线收缩压每升高10 mmHg,功能结局良好的比值比为0.76(P=0.04);再通前收缩压每升高10 mmHg,比值比为0.65(P=0.011);基线平均动脉压每升高10 mmHg,比值比为0.76(P=0.05);再通前平均动脉压每升高10 mmHg,比值比为0.66(P=0.03)。再通前收缩压163 mmHg和平均动脉压117 mmHg为预测功能结局的判别阈值。作者认为需要前瞻性随机对照研究来确定血压是否为可行的治疗靶点。
要点
- 再通前收缩压每升高10 mmHg,3个月功能结局良好(mRS 0-2)的OR为0.65(P=0.011)。
- 再通前平均动脉压每升高10 mmHg,功能结局良好的OR为0.66(P=0.03)。
- 基线收缩压每升高10 mmHg,功能结局良好的OR为0.76(P=0.04);基线平均动脉压每升高10 mmHg,OR为0.76(P=0.05)。
- 再通前收缩压163 mmHg和平均动脉压117 mmHg为预测功能结局的判别阈值。
- 按方案进行的再通前血压降低与功能结局无显著关联。
适用人群与场景
- 接受血管内治疗的大血管闭塞卒中患者,来自单中心前瞻性研究的事后分析。
- 功能结局分析纳入139例成功再通(脑梗死溶栓分级2b-3)患者。
诊断标准与关键阈值
- 成功再通定义为脑梗死溶栓分级2b-3。
- 功能结局良好定义为3个月改良Rankin量表评分0-2分。
- 再通前收缩压163 mmHg和平均动脉压117 mmHg为预测功能结局的判别阈值。
研究设计与关键结果
- 研究类型为单中心前瞻性研究的事后分析,样本量139例,人群为成功再通的大血管闭塞卒中患者,平均年龄76(10.9)岁,平均美国国立卫生研究院卒中量表评分14.3(7.5),70例(43.5%)为左侧血管闭塞。
- 主要终点:基线收缩压每升高10 mmHg,3个月改良Rankin量表评分0-2分的OR为0.76(P=0.04);再通前收缩压每升高10 mmHg,OR为0.65(P=0.011)。
- 基线平均动脉压每升高10 mmHg,功能结局良好的OR为0.76(P=0.05);再通前平均动脉压每升高10 mmHg,OR为0.66(P=0.03)。
- 再通前收缩压163 mmHg和平均动脉压117 mmHg为预测功能结局的判别阈值。
- 按方案进行的再通前血压降低与功能结局无显著关联。
证据类型、等级与局限
- 证据类型:单中心前瞻性研究的事后分析。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,需要前瞻性随机对照研究来确定血压是否为可行的治疗靶点以改善结局。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Optimal blood pressure (BP) management during endovascular stroke treatment in patients with large-vessel occlusion is not well established. We aimed to investigate associations of BP during different phases of endovascular therapy with reperfusion and functional outcome.
METHODS: We performed a post hoc analysis of a single-center prospective study that evaluated a new simplified procedural sedation standard during endovascular therapy (Keep Evaluating Protocol Simplification in Managing Periinterventional Light Sedation for Endovascular Stroke Treatment). BP during endovascular therapy in patients was managed according to protocol. Data from four different phases (baseline, pre-recanalization, post recanalization, and post intervention) were obtained, and mean BP values, as well as changes in BP between different phases and reductions in systolic BP (SBP) and mean arterial pressure (MAP) from baseline to pre-recanalization, were used as exposure variables. The main outcome was a modified Rankin Scale score of 0-2 three months after admission. Secondary outcomes were successful reperfusion and change in the National Institutes of Health Stroke Scale score after 24 h. Multivariable linear and logistic regression models were used for statistical analysis.
RESULTS: Functional outcomes were analyzed in 139 patients with successful reperfusion (defined as thrombolysis in cerebral infarction grade 2b-3). The mean (standard deviation) age was 76 (10.9) years, the mean (standard deviation) National Institutes of Health Stroke Scale score was 14.3 (7.5), and 70 (43.5%) patients had a left-sided vessel occlusion. Favorable functional outcome (modified Rankin Scale score 0-2) was less likely with every 10-mm Hg increase in baseline (odds ratio [OR] 0.76, P = 0.04) and pre-recanalization (OR 0.65, P = 0.011) SBP. This was also found for baseline (OR 0.76, P = 0.05) and pre-recanalization MAP (OR 0.66, P = 0.03). The maximum Youden index in a receiver operating characteristics analysis revealed an SBP of 163 mm Hg and MAP of 117 mm Hg as discriminatory thresholds during the pre-recanalization phase to predict functional outcome.
CONCLUSIONS: In our protocol-based setting, intraprocedural pre-recanalization BP reductions during endovascular therapy were not associated with functional outcome. However, higher intraprocedural pre-recanalization SBP and MAP were associated with worse functional outcome. Prospective randomized controlled studies are needed to determine whether BP is a feasible treatment target for the modification of outcomes.
参考来源
- Chen M, Kronsteiner D, Pfaff J, et al. Hemodynamic Status During Endovascular Stroke Treatment: Association of Blood Pressure with Functional Outcome. Neurocrit Care. 2021. PMID: 34142339. doi:10.1007/s12028-021-01229-w
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。